Alpine Woods Capital Investors’s Antares Pharma, Inc. ATRS Stock Holding History

Alpine Woods Capital Investors’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-55,000	Closed	-$200K	–	232
2021 Q3	$200K	Sell	55,000 -14,000	-20%	-$56.6K	0.02%	216
2021 Q2	$301K	Hold	69,000	–	–	0.03%	211
2021 Q1	$284K	Hold	69,000	–	–	0.03%	211
2020 Q4	$275K	Hold	69,000	–	–	0.03%	204
2020 Q3	$186K	Hold	69,000	–	–	0.03%	232
2020 Q2	$190K	Hold	69,000	–	–	0.04%	243
2020 Q1	$163K	Buy	69,000 +24,000	+53%	+$81.6K	0.04%	243
2019 Q4	$212K	Buy	45,000 +29,000	+181%	+$119K	0.04%	242
2019 Q3	$54K	Hold	16,000	–	–	0.01%	262
2019 Q2	$53K	Buy	16,000 +6,000	+60%	+$17.4K	0.01%	272
2019 Q1	$30K	Buy	+10,000	New	+$32.4K	0.01%	259

Other funds holding ATRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Alpine Woods Capital Investors's ATRS Position: Q4 2021 in Review

Alpine Woods Capital Investors sold out of Antares Pharma, Inc. (ATRS) in Q4 2021, closing a stake of 55,000 shares — an estimated $200K sold.

Alpine Woods Capital Investors first reported a position in ATRS in Q1 2019 and held it in 11 quarters. The position peaked at $301K in Q2 2021. 162 funds tracked by Wall St. Rank hold ATRS as of Q4 2021.

Alpine Woods Capital Investors reported no remaining Antares Pharma, Inc. position as of Q4 2021 after selling out during the quarter.
Alpine Woods Capital Investors sold 55,000 Antares Pharma, Inc. shares in Q4 2021, an estimated $200K.
Alpine Woods Capital Investors first reported a position in Antares Pharma, Inc. in Q1 2019 and held it in 11 quarters.
Alpine Woods Capital Investors's Antares Pharma, Inc. position peaked at $301K in Q2 2021.
162 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2021.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2021, filed 3 Feb 2022.